A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.


Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter click here!

Has compassionate use ever sunk a drug?

Click here to read a recent International Union Against Tuberculosis and Lung Disease Editorial by RESIST-TB members, Sarah McAnaw, Carole Mitnick, and Bob Horsburgh.

“New treatments for a serious disease generate understandable excitement among patients with life-threatening conditions. As pharmaceutical companies consider compassionate use of experimental drugs, one factor is commonly cited as a barrier to such use: fear that adverse events incurred by patients during Compassionate Use/Expanded Access (CU/EA) will impede regulatory approval of the drug. Such concerns stem from the obligation to report adverse events—that are serious, unexpected, and suspected to be related to the investigational drug— experienced by patients during treatment under CU/ EA programs.1 Such reports, it is feared, will damage the future of the drug, particularly since adverse events may not be related to the experimental drug and patients taking such drugs are typically sicker than the average patient.2 Existing evidence, however, does not support the notion that such events jeopardize regulatory approval.” Click here to read the article in full. 

Recent News and Announcements

The International Journal of Tuberculosis and Lung Disease featuring RESIST-TB Steering Committee Members

The International Journal of Tuberculosis and Lung Disease has released its May publication featuring RESIST-TB Steering Committee Members C. Robert Horsburgh and Carole Mitnick as Guest Editors. This issue also features a supplemental publication by C. Robert Horsburgh and Amita Gupta titled, “MDR-TB in Children: Back to the Basics.” The International Journal of Tuberculosis and […]

Interactive civil society hearing in preparation for the UN High-Level Meeting on TB

“Interactive civil society hearing to be held on 4 June 2018 in preparation for the UN High-Level Meeting on TB.” April 2018 | Geneva: The President of the UN General Assembly has announced that the interactive civil society hearing will be held on 4 June 2018 at the United Nations in New York, as part […]

Presentation Announcement

Please join RESIST-TB on Thursday, April 5th from 08:00 – 09:00 EST (14:00 – 15:00 CET/SAST) for an exciting webinar about the current evidence and practices for the combined use of delamanid and bedaquiline for the treatment of MDR-TB. Dr. Cathy Hewison and Dr. Lorenzo Guglielmetti will be our presenters. Two new drugs for tuberculosis, delamanid and bedaquiline, have shown to be effective […]

WHO issues recommendations on management of isoniazid-resistant tuberculosis

“The emergence of drug-resistant TB is a major global health concern, which threatens the ambitious goals and progress set under the End TB Strategy. Isoniazid-resistant TB, which is present in 8% of TB cases worldwide, reduces treatment success in patients treated with the standard 6-month first-line regimen. The new WHO recommendations for the treatment of […]

New Guide to Shorter Regimen for Treating DR-TB

DR-TB STAT + TAG brief: Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis “Multidrug-resistant TB (MDR-TB) is a growing problem around the world, and is difficult to treat. In 2016, the World Health Organization (WHO) recommended a shorter regimen for treating MDR-TB. Now, data from a randomized controlled trial are available. The […]

Event Calendar

Social Media